Gossamer Bio Expects to Commence Global Registrational Phase 3 Trial of Seralutinib for Patients With PH-ILD in Mid-2025
Gossamer Bio Expects to Commence Global Registrational Phase 3 Trial of Seralutinib for Patients With PH-ILD in Mid-2025
gossamer bio预计在2025年中旬开始进行Seralutinib用于PH-ILD患者的全球注册第三期试验。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册